Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Inclusion Criteria:

• Willing to participate in the study and provide written informed consent.
• Male and female adults aged > 18 years.
• Must have NASH and fibrosis on a liver biopsy sample
• If a historical liver biopsy is used for Screening, obtained within 6 months prior toScreening;
• Subjects may have a diagnosis of T2DM

Exclusion Criteria:

• History or presence of liver disease (other than NAFLD or NASH)
• History or presence of cirrhosis and/or history or presence of hepatic decompensation